Adult Male Circumcision Not A Cost Effective Anti-HIV Tactic, Panel Of Economists Says

A panel of economists commissioned by the Copenhagen Consensus Centre who “conducted a first-ever cost-benefit analysis of the top AIDS-fighting approaches by comparing the costs of prevention and treatment options per lives saved … said Wednesday that adult male circumcision, a global priority for preventing HIV infection, is not nearly as cost-effective as other methods of prevention,” USA Today reports. “The World Bank and the U.S. State Department support a major push for adult male circumcision,” however the panel said that “more cost-effective ways to prevent the spread of the disease are an HIV vaccine, infant male circumcision, preventing mother-to-child transmission of the disease and making blood transfusions safe,” the newspaper writes.

The panel estimated the cost-benefit ratio for adult circumcisions to be 23:1, and “said increasing annual spending on an AIDS vaccine by $100 million would be a better investment because it could potentially eradicate the disease, even though the cost-benefit ratio, 12:1, is lower,” USA Today writes. However, “Marelize Gorgens, HIV prevention coordinator at the World Bank, disagreed with the economists, saying male circumcision is like a vaccine because it reduces the risk of infection by 60 percent,” according to the newspaper (Dorell, 9/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.